News

UK government tightens rules on drug trial results

BMJ 2008; 336 doi: 10.1136/bmj.39517.500961.DB (Published 13 March 2008)
Cite this as: BMJ 2008;336:576.3

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Rebecca Coombes
  1. 1London

    The UK government is to increase drug companies’ responsibility to pass on information about clinical trials.

    The move comes after the regulators announced last week that it could not prosecute GlaxoSmithKline (GSK) for non-disclosure of trial data that showed it was unsafe for children younger than 18 to take the antidepressant paroxetine (Seroxat).

    The Medicines and Healthcare Products Regulatory Agency (MHRA) issued the final report of its four year investigation into GlaxoSmithKline, during which investigators sifted through one million pages of evidence. It concluded that the drug company hadn’t broken the law but criticised it for not reporting the information earlier. GlaxoSmithKline denied it had …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular